Skip to Content

Relatlimab + nivolumab: a potential new combination in first-line advanced melanoma

In this MEDtalk, Marco Donia, Center for Cancer Immune Therapy, Herlev Hospital, Denmark, gives his perspective of the data from RELATIVITY-047 presented by Evan J. Lipson during ASCO Virtual 2021.

Get access to the article

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top